Celsion Co. (NASDAQ:CLSN) CEO Michael H. Tardugno acquired 7,500 shares of the business’s stock in a transaction dated Monday, October 29th. The shares were purchased at an average price of $2.06 per share, with a total value of $15,450.00. Following the transaction, the chief executive officer now owns 27,700 shares of the company’s stock, valued at $57,062. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of Celsion stock opened at $2.06 on Wednesday. The stock has a market cap of $40.48 million, a PE ratio of -0.86 and a beta of 1.12. The company has a quick ratio of 4.23, a current ratio of 4.23 and a debt-to-equity ratio of 0.48. Celsion Co. has a twelve month low of $1.75 and a twelve month high of $3.96.
Celsion (NASDAQ:CLSN) last issued its quarterly earnings data on Tuesday, August 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.19). The firm had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.13 million. Celsion had a negative net margin of 4,479.42% and a negative return on equity of 109.99%. Analysts anticipate that Celsion Co. will post -1.17 earnings per share for the current fiscal year.
Separately, Zacks Investment Research lowered Celsion from a “hold” rating to a “sell” rating in a research report on Monday, August 20th.
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer.
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.